Chlortetracycline

Summary

Chlortetracycline (CHEMBL404520) is an approved small-molecule antiprotozoal drug (ATC D06AA02); indicated across 4 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D06AA02 (+3 more)
• Indications: 4 conditions
• Chemistry: 478.9 Da · C22H23ClN2O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL404520
Name	Chlortetracycline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54675777
ChEBI	CHEBI:27644
ATC	D06AA02, J01AA03, S01AA02, A01AB21
Molecular formula	C22H23ClN2O8
Molecular weight	478.9
InChIKey	DHPRQBPJLMKORJ-XRNKAMNCSA-N

SMILES: C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)N)N(C)C)O

IUPAC name: (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide

ChEBI definition: A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.

Pharmacological roles (ChEBI): antiprotozoal drug, fluorescent probe, calcium ionophore, antibacterial drug.

Also known as: Chlorotetracycline, Chlortetracycline, Clortetraciclina, E702, chlortetracycline, chlorotetracycline, CHLORTETRACYCLINE, CHLORTETRACYCLINE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL2106006, CHEMBL2146063, CHEMBL2146100

Patent coverage: 10,146 distinct patent families (27,546 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 26,923 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 3’,5’-cyclic-AMP phosphodiesterase 4A, Protein-arginine deiminase type-4.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888
osteomyelitis	0	MONDO:0005246	EFO:0003102

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).